



Luitpold Pharmaceuticals, Inc., US Physician Payments Report
January 1, 2016 through December 31, 2016

Payee	Study Name	Principal Investigator / Lead Researcher Last Name	Principal Investigator / Lead Researcher First Name	City of PI / Lead Researcher	State of PI / Lead Researcher	Total
21ST CENTURY ONCOLOGY LLC	1V1T14037- A Double-Blind, Multi-Center, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injactafer- Ferric Carboxymaltose- in the Treatment of Restless Legs Syndrome - RLS-	FERREIRA	MICHELLE	MEDLEY	FL	\$ 12,722.00
A TERRELONGE MD PA	1V1T13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injactafer- Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia-1	TERRELONGE	ANTONIO	MIAMI	FL	\$ 264.00
AFFILIATED PODIATRISTS PA	1V1T13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injactafer- Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia-1	NOAR	Mark	TOWSON	MD	\$ 378.00
AHI ATLANTA, LLC	1V1T13035	WOLF	DOUGLAS	ATLANTA	GA	\$ 29,430.00
ALL CARE CHIROPRACTIC & WELLNESS CENTER	1V1T14037- Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on Quality of Life and Resource Utilization, of Injactafer- vs. Int	Nair	Sanjosh	ORANGE CITY	FL	\$ 898.20
ANDERSON CLINICAL	1V1T13032 Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on Quality of Life and Resource Utilization, of Injactafer- vs. Int	Anderson	Donald	Redlands	CA	\$ 8,918.00
ANGELIQUE BARRETO M.D., P.C.	1V1T13032 Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on Quality of Life and Resource Utilization, of Injactafer- vs. Int	BARRETO	ANGELIQUE	OKLAHOMA CITY	OK	\$ 567.00
ANTIETAM ONCOLOGY&HEMATOLOGY GROUP.PC	1V1T14039- A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injactafer- ferric carboxymaltose injection- in Patients with Cancer- and Chemotherapy-related Anemia	HAMDAN	HIND	HAGERSTOWN	MD	\$ 45.00
ANTIETAM ONCOLOGY&HEMATOLOGY GROUP.PC	1V1T13032 Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on Quality of Life and Resource Utilization, of Injactafer- vs. Int	HAMDAN	HIND	HAGERSTOWN	MD	\$ 14,080.00
ARCHBOLD MEDICAL GROUP	1V1T13032 Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on Quality of Life and Resource Utilization, of Injactafer- vs. Int	COLEMAN	TERESA	THOMASVILLE	GA	\$ 210.00
ARIZONA CENTER FOR NEUROSURGERY LTD.	1V1T13032 Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on Quality of Life and Resource Utilization, of Injactafer- vs. Int	CORTEZ	ANDREW	PHOENIX	AZ	\$ 378.00
ARIZONA CENTER FOR NEUROSURGERY LTD.	1V1T13032 Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on Quality of Life and Resource Utilization, of Injactafer- vs. Int	MUSTAFA	ESMAT	PHOENIX	AZ	\$ 45.00
ARIZONA GASTROENTEROLOGY LTD	1V1T13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Efficacy and Safety of Injactafer- ferric carboxymaltose injection- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia-1	CONTRERAS	BRYAN	TUCSON	AZ	\$ 2,100.00
ASA CLINICAL RESEARCH	1V1T13032	RABIEI	ABBAS	JUPITER	FL	\$ 1,550.00
ASC DEVELOPMENT COMPANY, LLC	1V1T13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injactafer- Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia-1	HARDI	ROBERT	CHEVY CHASE	MD	\$ 420.00
ASHLAND BELLEFONTE OB-GYN	1V1T14039- A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injactafer- ferric carboxymaltose injection- in Patients with Cancer- and Chemotherapy-related Anemia	JAIN	KIRTI	ASHLAND	KY	\$ 567.00
ASSOCIATION IN ONCOLOGY & HEMATOLOGY	1V1T13032	GIANDHI	JITENDRA	KNOXVILLE	TN	\$ 2,157.20
BELMONT MEDICAL GROUP	1V1T13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injactafer- Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia-1	PRUITT	RONALD	NASHVILLE	TN	\$ 5,200.00
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK LLC	1V1T14039	Chaitowitz	Mark	NEW YORK	NY	\$ 12,014.00
BOND & STEELE CLINIC, P.A.	1V1T13032 Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on Quality of Life and Resource Utilization, of Injactafer- vs. Int	HLALAH	OSAMA	WINTER HAVEN	FL	\$ 567.00
BOND CLINIC PA	1V1T13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injactafer- Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia-1	HLALAH	OSAMA	WINTER HAVEN	FL	\$ 567.00
BRISTOL HOSPITAL INC	1V1T13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injactafer- Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia-1	ZAKKO	SALAM	BRISTOL	CT	\$ 4,673.00
BROOKWOOD INTERNAL MEDICINE, P.C.	1V1T13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injactafer- Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia-1	WILLIAMS	HAYES	VESTAVIA	AL	\$ 1,400.00
BROWARD MEDICAL PHYSICIAN ASSOCIATES INC	1V1T14037- A Double-Blind, Multi-Center, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injactafer- Ferric Carboxymaltose- in the Treatment of Restless Legs Syndrome - RLS-	Rielo	Diego	PEMBROKE PINES	FL	\$ 7,685.80
CANCER CARE CENTER	1V1T13032 Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on Quality of Life and Resource Utilization, of Injactafer- vs. Int	ROSS	DAVID	ROCKLEDGE	FL	\$ 1,030.00
CANCER CARE CENTERS OF BREVARD	1V1T14037- A Double-Blind, Multi-Center, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injactafer- Ferric Carboxymaltose- in the Treatment of Restless Legs Syndrome - RLS-	ROSS	DAVID	ROCKLEDGE	FL	\$ 150.00
CARDIOVASCULAR SPECIALISTS OF THE CUMBERLANDS PL	1V1T13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injactafer- Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia-1	ADAMS	Mark	LONDON	KY	\$ 7,000.00
CEDARS SINAI MEDICAL CENTER	1V1T13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injactafer- Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia-1	MELMED	GIL	LOS ANGELES	CA	\$ 2,188.00
CENTER FOR ADVANCED GASTROENTEROLOGY LLC	1V1T13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injactafer- Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia-1	HLIAL	RAOUF	MAITLAND	FL	\$ 4,200.00
CENTER FOR BRAIN AND NEURO CARE LLC	1V1T14037- A Double-Blind, Multi-Center, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injactafer- Ferric Carboxymaltose- in the Treatment of Restless Legs Syndrome - RLS-	GUNAWARDANE	RUWANI	ELLCOTT CITY	MD	\$ 9,150.00
CENTER FOR CANCER & BLOOD	1V1T13032 Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on Quality of Life and Resource Utilization, of Injactafer- vs. Int	BOCCIA	RALPH	BETHESDA	MD	\$ 4,760.00
CENTER FOR CANCER AND BLOOD DISORDERS	1V1T14039- A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injactafer- ferric carboxymaltose injection- in Patients with Cancer- and Chemotherapy-related Anemia	BOCCIA	RALPH	BETHESDA	MD	\$ 7,000.00
CENTER FOR CANCER AND BLOOD DISORDERS	1V1T13032 Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on Quality of Life and Resource Utilization, of Injactafer- vs. Int	BOCCIA	RALPH	BETHESDA	MD	\$ 6,710.00
CENTRAL KENTUCKY RESEARCH ASSOCIATION INC.	1V1T14037- A Double-Blind, Multi-Center, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injactafer- Ferric Carboxymaltose- in the Treatment of Iron Deficient patients with Fibromyalgia.	ADAMS	Mark	LONDON	KY	\$ 4,100.00
CHAD BOOMERSHINE	1V1T13035	WILSON	JASON	CHARLOTTE	NC	\$ 850.50
CHARLOTTE GASTROENTEROLOGY & HEPATOLOGY, PLLC	1V1T13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injactafer- Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia-1	WILSON	JASON	HUNTERSVILLE	NC	\$ 7,800.00
CHARLOTTE GASTROENTEROLOGY & HEPATOLOGY, PLLC	1V1T13032 Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on Quality of Life and Resource Utilization, of Injactafer- vs. Int	WILSON	JASON	HUNTERSVILLE	NC	\$ 7,800.00
CHI ST VINCENT HOSPITAL HOT SPRINGS	1V1T14037- A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injactafer- ferric carboxymaltose injection- in Patients with Cancer- and Chemotherapy-related Anemia	CLEVELAND	LYNN	HOT SPRINGS	AR	\$ 435.00
CINCINNATI CHILDREN'S HOSPITAL	Vonofzer Pediatric Registry	VANDEVORDE	RENE	NASHVILLE	TN	\$ 6,400.00

Payer	Study Name	Principal Investigator / Lead Researcher Last Name	Principal Investigator / Lead Researcher First Name	City of PI / Lead Researcher	State of PI / Lead Researcher	Total
CLEVELAND CLINIC FOUNDATION	Venofor Pediatric Registry	DELL	KATHERINE	CLEVELAND	OH	\$ 400.00
CLINICAL RESEARCH SOLUTIONS	1VIT14038	BOOMERSHINE	CHAD	NASHVILLE	TN	\$ 5,952.50
Clinical Research Solutions, LLC	1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injactafer - Ferric Carboxymaltose - vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia - I	FRIDENBERG	KEITH	MENTOR	OH	\$ 10,720.00
Clinical Research Solutions, LLC	1VIT14038- A Blinded, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injactafer - Ferric Carboxymaltose- in the Treatment of Iron Deficient patients with Fibromyalgia.	BOOMERSHINE	CHAD	NASHVILLE	TN	\$ 136,696.25
COASTAL CAROLINA HEALTH CARE PA	1VIT13032 Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on Quality of Life and Resource Utilization, of Injactafer- vs. Int	MONTERO	MANUEL	NEW BERN	NC	\$ 378.00
Coastal Clinical Research Inc	1VIT14037	LEDET	MICHAEL	MOBILE	AL	\$ 19,974.50
Coastal Clinical Research Inc	1VIT14039	LEDET	MICHAEL	MOBILE	AL	\$ 13,680.95
COMPASSIONATE CANCER CARE MEDICAL GROUP, INC.	1VIT14039	CHOI	BRIAN	RIVERSIDE	CA	\$ 11,120.00
COMPASSIONATE CANCER CARE MEDICAL GROUP, INC.	1VIT14039	JHANGIANI	HARESH	FOUNTAIN VALLEY	CA	\$ 16,625.00
CONSULTANTS IN NEUROLOGY, PA	1VIT14037- A Double-Blind, Multi-Center, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injactafer - Ferric Carboxymaltose- in the Treatment of Restless Legs Syndrome - RLS-	ROWE	VERNON	LENEXA	KS	\$ 7,567.00
DANA FARBER CANCER INSTITUTE	1VIT13032 Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on Quality of Life and Resource Utilization, of Injactafer- vs. Int	OKAM	MAUREEN	BROOKLINE	MA	\$ 1,575.00
DARTMOUTH-HITCHCOCK CLINIC SSP SPECIALTY SERVICES	1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injactafer - Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia - I	SIEGEL	COREY	LEBANON	NH	\$ 1,400.00
DAVID KUDROW	1VIT14037					\$ 14,000.00
DELTA ONCOLOGY ASSOCIATES PC	1VIT13032 Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on Quality of Life and Resource Utilization, of Injactafer- vs. Int	SHABAZZ	LLOYD	PORTSMOUTH	VA	\$ 420.00
DESERT NEUROLOGY ASSOCIATES, LLC	1VIT14037- A Double-Blind, Multi-Center, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injactafer - Ferric Carboxymaltose- in the Treatment of Restless Legs Syndrome - RLS-	THEUVENET	NICOLE	HENDERSON	NV	\$ 9,717.00
DESERT VALLEY MEDICAL GROUP, INC.	1VIT14037- A Double-Blind, Multi-Center, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injactafer - Ferric Carboxymaltose- in the Treatment of Restless Legs Syndrome - RLS-	Anderson	Dennis	SAN BERNARDINO	CA	\$ 7,000.00
DESERT VALLEY MEDICAL GROUP, INC.	1VIT14037- A Double-Blind, Multi-Center, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injactafer - Ferric Carboxymaltose- in the Treatment of Restless Legs Syndrome - RLS-	Anderson	Donald	Redlands	CA	\$ 630.00
Desert Valley Research	1VIT14037	Anderson	Dennis	SAN BERNARDINO	CA	\$ 17,348.00
DHARAM KUMBHANI	1VIT14037					\$ 3,300.00
DIGESTIVECARE, INC.	1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injactafer - Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia - I	STONE	USA	BEAVERCREEK	OH	\$ 45.00
DREXEL UNIVERSITY	1VIT13032 Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on Quality of Life and Resource Utilization, of Injactafer- vs. Int	STYLER	MICHAEL	PHILADELPHIA	PA	\$ 1,470.00
EAST CAROLINA UNIVERSITY	Venofor Pediatric Registry	HIDALGO	GUILLERMO	CHARLOTTE	NC	\$ 400.00
EDGARDO SANTIAGO-GUZMAN	1VIT14039					\$ 7,080.00
EDGE MONT MEDICAL CLINIC	Venofor Pediatric Registry	ZARITSKY	JOSHUA	WILMINGTON	DE	\$ 7,400.00
EGRET BAY NEUROLOGY, PA	1VIT14037- A Double-Blind, Multi-Center, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injactafer - Ferric Carboxymaltose- in the Treatment of Restless Legs Syndrome - RLS-	FUJII	MAVIS	HOUSTON	TX	\$ 16,717.00
EHCA JOHNS CREEK, LLC	1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injactafer - Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia - I	SALZBERG	BRUCE	SUWANEE	GA	\$ 378.00
Elite Research Institute	1VIT14037	Riefo	Diego	PEMBROKE PINES	FL	\$ 4,500.00
ELOY ROMAN MD PA	1VIT14039- A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injactafer - ferric carboxymaltose injection- in Patients with Cancer- and Chemotherapy-related Anemia	ROMAN	ELOY	MIAMI	FL	\$ 19,955.00
ELOY ROMAN MD PA	1VIT14039- A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injactafer - ferric carboxymaltose injection- in Patients with Cancer- and Chemotherapy-related Anemia	YANEZ	GIRALT	PEMBROKE PINES	FL	\$ 7,898.20
EMORY DIALYSIS, LLC	1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injactafer - Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia - I	WOLF	DOUGLAS	ATLANTA	GA	\$ 4,500.00
ENDOSCOPIC MICROSURGERY ASSOCIATES	1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injactafer - Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia - I	NOAR	Mark	TOWSON	MD	\$ 232.00
ERIKA DRIVER-DUNCKLEY	1VIT14037					\$ 7,000.00
ETMC CANCER INSTITUTE CLINIC TRIALS	1VIT14039	DRODER	ROBERT	TYLER	TX	\$ 4,000.00
ETMC CANCER INSTITUTE CLINIC TRIALS	1VIT14039	GROSS	GARY	TYLER	TX	\$ 4,000.00
EVECON INC	1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injactafer - Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia - I	WEBER	JOHN	TROY	MI	\$ 6,266.00
Feinstein Institute	1VIT13032	SWAMINATH	ARUN	NEW YORK	NY	\$ 815.20
FLORIDA HEALTH SCIENCES CENTER INC	1VIT14039- A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injactafer - ferric carboxymaltose injection- in Patients with Cancer- and Chemotherapy-related Anemia	JAGLAL	MICHAEL	TAMPA	FL	\$ 567.00
FORT COLLINS NEUROLOGY PC	1VIT14037- A Double-Blind, Multi-Center, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injactafer - Ferric Carboxymaltose- in the Treatment of Restless Legs Syndrome - RLS-	CURIEL	MICHAEL	FORT COLLINS	CO	\$ 9,717.00
GARY GROSS	1VIT14039					\$ 7,080.00
GASTROENTEROLOGY ASSOCIATES	1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injactafer - Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia - I	HOMOKY	DOUGLAS	KINGSPORT	TN	\$ 2,200.00
GASTROENTEROLOGY ASSOCIATES OF DOTHAN, PC	1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injactafer - Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia - I	RUTLAND	TRAVIS	DOTHAN	AL	\$ 2,800.00
GASTROENTEROLOGY CLINIC OF ACADIANA	1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injactafer - Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia - I	ARTERBURN	JAMES	LAFAYETTE	LA	\$ 2,100.00
GASTROENTEROLOGY CLINIC OF SAN ANTONIO, P.A.	1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injactafer - Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia - I	BULLOCK	JEFF	SAN ANTONIO	TX	\$ 36,080.00
GASTROENTEROLOGY CLINIC OF SAN ANTONIO, P.A.	1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injactafer - Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia - I	RANDALL	CHARLES	SAN ANTONIO	TX	\$ 15,978.00
GASTROENTEROLOGY CLINIC OF SAN ANTONIO, P.A.	1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injactafer - Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia - I	RINESMITH	SCOTT	LIMA	OH	\$ 2,038.00

Payee	Study Name	Principal Investigator / Lead Researcher Last Name	Principal Investigator / Lead Researcher First Name	City of PI / Lead Researcher	State of PI / Lead Researcher	Total
GASTRO-INTESTINAL ASSOCIATES, INC.	1V1T13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer - Ferric Carboxymaltose - vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -I	RINSMITH	SCOTT	LIMA	OH	\$ 1,500.00
GASTROINTESTINAL SPECIALISTS, A.M.C	1V1T13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer - Ferric Carboxymaltose - vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -I	JOHNSON	LAWRENCE	BOSSIER CITY	LA	\$ 6,772.00
CGCA PHYSICIANS INC.	1V1T13032 Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on Quality of Life and Resource Utilization, of Injectafer -vs. Int	CHOKSHI	MANISH	CINCINNATI	OH	\$ 50.00
CGCA PHYSICIANS INC.	1V1T13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer - Ferric Carboxymaltose - vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -I	WEBER	JOHN	TROY	MI	\$ 378.00
GENERAL HOSPITAL CORPORATION	1V1T14039- A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injectafer- ferric carboxymaltose injection- in Patients with Cancer- and Chemotherapy-related Anemia	WINKELMAN	JOHN	BOSTON	MA	\$ 8,879.00
GEORGETOWN RADIATION ONCOLOGY PLLC	1V1T14039- A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injectafer- ferric carboxymaltose injection- in Patients with Cancer- and Chemotherapy-related Anemia	DOWDIE	BENJAMIN	GEORGETOWN	TX	\$ 7,080.00
GETTYSBURG CANCER CENTER	1V1T14039- A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injectafer- ferric carboxymaltose injection- in Patients with Cancer- and Chemotherapy-related Anemia	KHAIIR	TINA	GETTYSBURG	PA	\$ 26,471.11
GLOBAL CANCER RESEARCH INSTITUTE, INC.	1V1T13032 Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on Quality of Life and Resource Utilization, of Injectafer -vs. Int	BUI	LYNNE	GILROY	CA	\$ 4,650.00
GREAT FALLS CLINIC LLP	1V1T13032 Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on Quality of Life and Resource Utilization, of Injectafer -vs. Int	GUTER	KARL	GREAT FALLS	MT	\$ 5,743.00
GREAT FALLS CLINIC LLP	1V1T13032 Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on Quality of Life and Resource Utilization, of Injectafer -vs. Int	GUTER	KARL	GREAT FALLS	MT	\$ 465.00
GUILFORD NEUROLOGIC ASSOCIATES, INC.	1V1T14037- A Double-Blind, Multi-Center, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer- Ferric Carboxymaltose- in the Treatment of Restless Legs Syndrome - RLS-	DOHMEIER	CARMEN	GREENSBORO	NC	\$ 9,717.00
HASSAN TAHSIDAR	1V1T14039- A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injectafer- ferric carboxymaltose injection- in Patients with Cancer- and Chemotherapy-related Anemia	HLALAH	OSAMA	WINTER HAVEN	FL	\$ 14,160.00
HEARINGLIFE USA	1V1T13032 Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on Quality of Life and Resource Utilization, of Injectafer -vs. Int	HAUT	MITCHELL	CANTON	OH	\$ 7,000.00
HEMATOLOGY & ONCOLOGY ASSOCIATES, INC	1V1T13032 Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on Quality of Life and Resource Utilization, of Injectafer -vs. Int	HAUT	MITCHELL	CANTON	OH	\$ 1,800.00
HEMATOLOGY ONCOLOGY CLINIC LLP	1V1T13032 Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on Quality of Life and Resource Utilization, of Injectafer -vs. Int	CASTINE	MICHAEL	BATON ROUGE	LA	\$ 378.00
INFUSION ASSOCIATES PC	1V1T13032 Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on Quality of Life and Resource Utilization, of Injectafer -vs. Int	NEDD	KHAN	GRAND RAPIDS	MI	\$ 3,575.00
INFUSION ASSOCIATES PC	1V1T13032 Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on Quality of Life and Resource Utilization, of Injectafer -vs. Int	NEDD	KHAN	GRAND RAPIDS	MI	\$ 903.00
INSIGHT GASTROENTEROLOGY AND HEPATOLOGY, INC	1V1T13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer - Ferric Carboxymaltose - vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -I	LAMET	Mark	HOLLYWOOD	FL	\$ 13,042.00
INTRAFUSION	1V1T14037	DENGLER	JOHN	JOHNSON CITY	TN	\$ 15,013.00
INTRAFUSION	1V1T14037	DIXIT	SHANKER	LAS VEGAS	NV	\$ 12,240.00
INTRAFUSION	1V1T14037	DOHMEIER	CARMEN	GREENSBORO	NC	\$ 4,742.00
INTRAFUSION	1V1T14037	FUJII	MAVIS	HOUSTON	TX	\$ 5,490.00
INTRAFUSION	1V1T14037	GUNAWARDANE	RUVWANI	FULTON	MD	\$ 1,888.00
INTRAFUSION	1V1T14037	HIDALGO	GONZALO	ALEXANDRIA	LA	\$ 9,048.00
INTRAFUSION	1V1T14037	MANDELL	HOWARD	ROCK HILL	SC	\$ 9,489.00
INTRAFUSION	1V1T14037	SAAD	JULIETTE	SPARTANBURG	SC	\$ 7,839.00
INTRAFUSION RESEARCH NETWORK	1V1T14037	DENGLER	JOHN	JOHNSON CITY	TN	\$ 13,965.00
INTRAFUSION RESEARCH NETWORK	1V1T14037	DIXIT	SHANKER	LAS VEGAS	NV	\$ 6,561.00
INTRAFUSION RESEARCH NETWORK	1V1T14037	DOHMEIER	CARMEN	GREENSBORO	NC	\$ 3,270.00
INTRAFUSION RESEARCH NETWORK	1V1T14037	SAAD	JULIETTE	SPARTANBURG	SC	\$ 3,050.00
INTRAFUSION RESEARCH NETWORK	1V1T14037	THELUVENET	NICOLE	HENDERSON	NV	\$ 3,050.00
IRONWOOD PHYSICIANS	1V1T13032	KALMADI	SUJITH	CHANDLER	AZ	\$ 120.00
IRONWOOD PHYSICIANS	1V1T13032	SHTIVELBAND	MIKHAIL	CHANDLER	AZ	\$ 870.00
IRONWOOD PHYSICIANS, PC	1V1T13032 Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on Quality of Life and Resource Utilization, of Injectafer -vs. Int	KALMADI	SUJITH	CHANDLER	AZ	\$ 210.00
IRONWOOD PHYSICIANS, PC	1V1T13032 Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on Quality of Life and Resource Utilization, of Injectafer -vs. Int	SHTIVELBAND	MIKHAIL	CHANDLER	AZ	\$ 420.00
JANET KWATKOWSKI	1V1T14039- A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injectafer- ferric carboxymaltose injection- in Patients with Cancer- and Chemotherapy-related Anemia	SHTIVELBAND	MIKHAIL	CHANDLER	AZ	\$ 1,800.00
JITENDRA G. GANDHI	1V1T13032 Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on Quality of Life and Resource Utilization, of Injectafer -vs. Int	GANDHI	JITENDRA	KNOXVILLE	TN	\$ 50.00
JOHN D ARCHBOLD MEMORIAL	1V1T14039- A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injectafer- ferric carboxymaltose injection- in Patients with Cancer- and Chemotherapy-related Anemia	COLEMAN	TERESA	THOMASVILLE	GA	\$ 15,537.50
JOHN DENGLER	1V1T14037- A Double-Blind, Multi-Center, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer- Ferric Carboxymaltose- in the Treatment of Restless Legs Syndrome - RLS-	ADAMS	Mark	LONDON	KY	\$ 8,400.00
JOHN L. BUJER, M.D., PSC	1V1T14037	ADAMS	Mark	LONDON	KY	\$ 1,042.20
JOHN WINKELMAN	1SPR11009-A PLACEBO-CONTROLLED, DOUBLE-BLIND, CROSSOVER STUDY TO EVALUATE THE EFFICACY OF KETOROLAC NASAL SPRAY - SPRIX- AS COMPARED TO SUMATRIPTAN NASAL SPRAY AND PLACEBO FOR THE ACUTE ABORTIVE TREATMENT OF MIGRAINE ATTACKS	PETERLIN	BARBARA	BALTIMORE	MD	\$ 31,125.00
JOHNS HOPKINS UNIVERSITY	Venofen Pediatric Registry	NEU	ALICIA	BALTIMORE	MD	\$ 400.00
JOHNS HOPKINS UNIVERSITY	1V1T13032 Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on Quality of Life and Resource Utilization, of Injectafer -vs. Int	SUH	JASON	JOLIET	IL	\$ 289.00
JOLIET ONCOLOGY HEMATOLOGY	1V1T14039- A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injectafer- ferric carboxymaltose injection- in Patients with Cancer- and Chemotherapy-related Anemia	SUH	JASON	JOLIET	IL	\$ 7,647.00
JOLIET ONCOLOGY HEMATOLOGY	1V1T14039- A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injectafer- ferric carboxymaltose injection- in Patients with Cancer- and Chemotherapy-related Anemia	SUH	JASON	JOLIET	IL	\$ 9,206.25
JOLIET ONCOLOGY HEMATOLOGY ASSOCIATES LTD	1V1T14039- A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injectafer- ferric carboxymaltose injection- in Patients with Cancer- and Chemotherapy-related Anemia	SUH	JASON	JOLIET	IL	\$ 9,206.25
KINSTON MEDICAL SPECIALISTS PA	1V1T13032	MARILLEY	Mark	KINSTON	NC	\$ 75.00
KINSTON MEDICAL SPECIALISTS PA	1V1T13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer - Ferric Carboxymaltose - vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -I	MARILLEY	Mark	KINSTON	NC	\$ 6,358.00
KINSTON MEDICAL SPECIALISTS PA	1V1T14037- A Double-Blind, Multi-Center, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer- Ferric Carboxymaltose- in the Treatment of Restless Legs Syndrome - RLS-	MARILLEY	Mark	KINSTON	NC	\$ 4,200.00
KINSTON MEDICAL SPECIALISTS PA	1V1T14037- A Double-Blind, Multi-Center, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer- Ferric Carboxymaltose- in the Treatment of Restless Legs Syndrome - RLS-	WATSON	PETER	KINSTON	NC	\$ 567.00
KINSTON MEDICAL SPECIALISTS PA	1V1T14039- A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injectafer- ferric carboxymaltose injection- in Patients with Cancer- and Chemotherapy-related Anemia	WATSON	PETER	KINSTON	NC	\$ 16,716.00
KINSTON MEDICAL SPECIALISTS PA	1V1T14039- A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injectafer- ferric carboxymaltose injection- in Patients with Cancer- and Chemotherapy-related Anemia	WATSON	PETER	KINSTON	NC	\$ 340.10
KINSTON MEDICAL SPECIALISTS PA	1V1T14039- A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injectafer- ferric carboxymaltose injection- in Patients with Cancer- and Chemotherapy-related Anemia	WATSON	PETER	KINSTON	NC	\$ 16,716.00
KIRTI K JAIN, MD PSC	1V1T13032 Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on Quality of Life and Resource Utilization, of Injectafer -vs. Int	JAIN	KIRTI	ASHLAND	KY	\$ 14,647.00
LAFAYETTE HEALTH VENTURES, INC	1V1T13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer - Ferric Carboxymaltose - vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia -I	ARTERBURN	JAMES	LAFAYETTE	LA	\$ 5,420.00
LAKES RESEARCH	1V1T14039- A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injectafer- ferric carboxymaltose injection- in Patients with Cancer- and Chemotherapy-related Anemia	ROMAN	ELOY	MIAMI	FL	\$ 11,287.00
MADHURI BAJAJ	1V1T14039- A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injectafer- ferric carboxymaltose injection- in Patients with Cancer- and Chemotherapy-related Anemia	ROMAN	ELOY	MIAMI	FL	\$ 7,000.00
MARK GOETTING	1V1T14037	ROMAN	ELOY	MIAMI	FL	\$ 14,000.00

Payee	Study Name	Principal Investigator / Lead Researcher Last Name	Principal Investigator / Lead Researcher First Name	City of PI / Lead Researcher	State of PI / Lead Researcher	Total
MARK LAMET MD PA	1V1T13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injefater- Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia- I	LAMET	Mark	HOLLYWOOD	FL	\$ 198.29
Mary Hitchcock Memorial Hospital	1V1T13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injefater- Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia- I	SIEGEL	COREY	LEBANON	NH	\$ 16,685.00
MASSACHUSETTS GENERAL HOSPITAL	1V1T14037- A Double-Blind, Multi-Center, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injefater- Ferric Carboxymaltose- in the Treatment of Restless Legs Syndrome- RLS-	WINKELMAN	JOHN	BOSTON	MA	\$ 35,709.00
MASSACHUSETTS GENERAL HOSPITAL	1V1T14037	WINKELMAN	JOHN	BOSTON	MA	\$ 10,390.00
MAYO CLINIC HOSPITAL	1V1T13032 Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on Quality of Life and Resource Utilization, of Injefater- vs. Int	DRIVER-DUNCKLEY	ERIKA	SCOTTSDALE	AZ	\$ 14,500.00
MEDICAL CONSULTANTS MANAGEMENT, LLC	1V1T13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injefater- Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia- I	RABIEI	ABBAS	JUPITER	FL	\$ 45.00
Medical Research Center of CT	1V1T13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injefater- Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia- I	GINSBURG	PHILIP	HAMDEN	CT	\$ 3,178.00
MICHIANA DORESWAMY	1V1T14037					\$ 8,400.00
METHODIST HOSPITAL	1V1T14037	ONDO	WILLIAM	HOUSTON	TX	\$ 23,595.00
MICHAEL LEDET	1V1T14037					\$ 4,200.00
MICHIANA HEMATOLOGY-ONCOLOGY P C	1V1T14039- A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injefater- ferric carboxymaltose injection- in Patients with Cancer- and Chemotherapy-related Anemia	BRAUN	EDUARDO	SOUTH BEND	IN	\$ 13,704.10
MICHIANA HEMATOLOGY-ONCOLOGY, P.C	1V1T14039- A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injefater- ferric carboxymaltose injection- in Patients with Cancer- and Chemotherapy-related Anemia	BRAUN	EDUARDO	SOUTH BEND	IN	\$ 630.00
MID-ILLINOIS HEMATOLOGY ONCOLOGY ASSOCIATES LTD	1V1T14039	MIGAS	JOHN	NORMAL	IL	\$ 2,965.00
MID-ILLINOIS HEMATOLOGY ONCOLOGY ASSOCIATES LTD	1V1T14039- A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injefater- ferric carboxymaltose injection- in Patients with Cancer- and Chemotherapy-related Anemia	MIGAS	JOHN	NORMAL	IL	\$ 7,647.00
MILTON S. HERSHEY MEDICAL CENTER	Venofier Pediatric Registry	WASSNER	STEVEN	HERSHEY	PA	\$ 600.00
MOHAMMED BARI	1V1T14037- A Double-Blind, Multi-Center, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injefater- Ferric Carboxymaltose- in the Treatment of Restless Legs Syndrome- RLS-	BARI	MOHAMMED	NATIONAL CITY	CA	\$ 20,238.00
MOHAMMED BARI, M. D. INC	1V1T14039	Chaitowitz	Mark	NEW YORK	NY	\$ 11,753.90
MONTEFIORE MEDICAL CENTER	1V1T13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injefater- Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia- I	PRUITT	RONALD	NASHVILLE	TN	\$ 567.00
NASHVILLE SURGICAL ASSOCIATES, PLLC	1V1T14037	FERRERIA	MICHELLE	BOCA RATON	FL	\$ 6,761.00
NEUROLOGY OFFICES OF SOUTH FLORIDA PLLC	1V1T14039- A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injefater- ferric carboxymaltose injection- in Patients with Cancer- and Chemotherapy-related Anemia	HILL	JULIAN	TUPELO	MS	\$ 9,020.00
NORTH MISSISSIPPI HEMATOLOGY & ONCOLOGY ASSOC.	1V1T14039	HILL	JULIAN	TUPELO	MS	\$ 45,898.00
NORTH MISSISSIPPI MEDICAL CENTER	1V1T13032 Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on Quality of Life and Resource Utilization, of Injefater- vs. Int	HILL	JULIAN	TUPELO	MS	\$ 420.00
NORTH MISSISSIPPI MEDICAL CENTER, INC	1V1T14039- A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injefater- ferric carboxymaltose injection- in Patients with Cancer- and Chemotherapy-related Anemia	HILL	JULIAN	TUPELO	MS	\$ 5,900.00
NORTH MISSISSIPPI MEDICAL CENTER, INC	1V1T13032 Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on Quality of Life and Resource Utilization, of Injefater- vs. Int	SWAMINATH	ARUN	NEW YORK	NY	\$ 45.00
NORTH SHORE UNIVERSITY HOSPITAL HOMECARE	1V1T13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injefater- Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia- I	WOHLMAN	ROBERT	BELLEVEUE	WA	\$ 378.00
NORTHWEST GASTROENTEROLOGY ASSOCIATES, INC., P.A	1V1T13032	HOW	HELEN	LOUISVILLE	KY	\$ 2,165.00
NORTON HEALTHCARE	1V1T13032 Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on Quality of Life and Resource Utilization, of Injefater- vs. Int	HOW	HELEN	CHICAGO	IL	\$ 1,500.00
NORTON HEALTHCARE	1V1T13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injefater- Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia- I	WILSON	JASON	HUNTERSVILLE	NC	\$ 1,400.00
NOVANT MEDICAL GROUP INC	1V1T13035	TERRELONGE	ANTONIO	MIAMI	FL	\$ 20,955.00
OCEAN BLUE MEDICAL RESEARCH CENTER, INC	1V1T13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injefater- Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia- I	TERRELONGE	ANTONIO	MIAMI	FL	\$ 378.00
OCEAN BLUE MEDICAL RESEARCH CENTER, INC	1V1T13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injefater- Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia- I	TERRELONGE	ANTONIO	MIAMI	FL	\$ 378.00
Ohio State University Hospital	1V1T13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injefater- Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia- I	ZHANG	CHENG	COLUMBUS	OH	\$ 4,200.00
OMEGA RESEARCH	1V1T13032	Nair	Saritosh	ORANGE CITY	FL	\$ 3,080.00
ONCOLOGY-HEMATOLOGY	1V1T14039	BAJAJ	MADHURI	PEORIA	IL	\$ 13,822.00
ONCOLOGY-HEMATOLOGY ASSOCIATES OF CENTRAL ILLINOIS	1V1T14039- A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injefater- ferric carboxymaltose injection- in Patients with Cancer- and Chemotherapy-related Anemia	BAJAJ	MADHURI	PEORIA	IL	\$ 567.00
ORCHARD HEALTHCARE	1V1T13032	OLIFF	IRA	SKOKIE	IL	\$ 2,660.00
PAUL WYLLIE	1V1T14037					\$ 7,000.00
PHARMASEEK FINANCIAL SERVICES LLC	1V1T14037	GOETTING	Mark	PORTAGE	MI	\$ 5,742.00
PHARMASEEK FINANCIAL SERVICES LLC	1V1T14037	KRAINSON	JAMES	MIAMI	FL	\$ 5,742.00
PHARMASEEK FINANCIAL SERVICES LLC	1V1T14037	NGUYEN	CHRISTINA	GARDEN GROVE	CA	\$ 5,742.00
PHARMASEEK FINANCIAL SERVICES LLC	1V1T14039	BARBRANCO	ELIZABETH	PONCE	PR	\$ 6,742.00
PHARMASEEK FINANCIAL SERVICES LLC	1V1T14039	Santiago-Guzman	Edgardo	San Juan	PR	\$ 8,191.50
PHARMASEEK FINANCIAL SERVICES LLC	1V1T14037- A Double-Blind, Multi-Center, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injefater- Ferric Carboxymaltose- in the Treatment of Restless Legs Syndrome- RLS-	MANDELL	HOWARD	ROCK HILL	SC	\$ 9,217.00
PMC PHYSICIAN NETWORK	1V1T14037	WYLLIE	PAUL	LITTLE ROCK	AR	\$ 23,775.60
PREFERRED RESEARCH	1V1T13032 Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on Quality of Life and Resource Utilization, of Injefater- vs. Int	GERSHENBAUM	BART	DAVIE	FL	\$ 50.00
PROFESSIONAL PAIN MANAGEMENT CLINIC INC	1V1T14037					\$ 3,300.00
RAKESH GAUR	1V1T13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injefater- Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia- I	RUTLAND	TRAVIS	DOTHAN	AL	\$ 13,650.00
RALEIGH DURHAM MEDICAL GROUP PA	1V1T14039	BOCCIA	RALPH	BETHESDA	MD	\$ 1,107.00
REGIONAL CANCER CARE ASSOCIATION	1V1T14039- A Double-Blind, Multi-Center, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injefater- Ferric Carboxymaltose- in the Treatment of Restless Legs Syndrome- RLS-	Anderson	Donald	Redlands	CA	\$ 7,000.00
RIVERSIDE/SAN BERNARDINO COUNTY INDIAN HEALTH, INC	1V1T14039					\$ 14,080.00
ROBERT DRODER	1V1T14039- A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injefater- ferric carboxymaltose injection- in Patients with Cancer- and Chemotherapy-related Anemia	ORCUTT	JAMES	CHARLESTON	SC	\$ 7,710.00
ROPER SAINT FRANCIS PHYSICIANS NETWORK	1V1T14037- A Double-Blind, Multi-Center, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injefater- Ferric Carboxymaltose- in the Treatment of Restless Legs Syndrome- RLS-	SAAD	JULIETTE	SPARTANBURG	SC	\$ 23,780.00
SAAD UPSTATE NEUROLOGY, P.A.	1V1T14039- A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injefater- ferric carboxymaltose injection- in Patients with Cancer- and Chemotherapy-related Anemia	SREENIVASAPPA	SHYLDRA	ROCKFORD	IL	\$ 7,080.00
SAINT ANTHONY MEDICAL CENTER	1V1T14039- A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injefater- ferric carboxymaltose injection- in Patients with Cancer- and Chemotherapy-related Anemia	SREENIVASAPPA	SHYLDRA	ROCKFORD	IL	\$ 7,080.00

Payee	Study Name	Principal Investigator / Lead Researcher Last Name	Principal Investigator / Lead Researcher First Name	City of PI / Lead Researcher	State of PI / Lead Researcher	Total
SAN ANTONIO GASTROENTEROLOGY ASSOCIATES, PA	1V1T13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injactafer- Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia-1	BULLOCK	JEFF	SAN ANTONIO	TX	\$ 3,500.00
SANTEE HEMATOLOGY ONCOLOGY INC	1V1T13032 Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on Quality of Life and Resource Utilization, of Injactafer- vs. Int	CLOWNEY	BILLY	SUMTER	SC	\$ 378.00
SATISH A. SHAH, M.D., P.C.	1V1T14039- A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injactafer- ferric carboxymaltose injection- in Patients with Cancer- and Chemotherapy-related Anemia	KHAIR	TINA	GETTYSBURG	PA	\$ 7,340.10
SATISH A. SHAH, M.D., P.C.	1V1T14039- A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injactafer- ferric carboxymaltose injection- in Patients with Cancer- and Chemotherapy-related Anemia	SHAH	SATISH	GETTYSBURG	PA	\$ 567.00
SE MISSOURI HOSPITAL	1V1T13032	MOSLEY	JAMES	CAPE GIRARDEAU	MO	\$ 1,240.00
SHANKER DIXIT	1V1T14037					\$ 4,200.00
SHANKER N DIXIT, MD PC	1V1T14037- A Double-Blind, Multi-Center, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injactafer- Ferric Carboxymaltose- in the Treatment of Restless Legs Syndrome - RLS-	DIXIT	SHANKER	LAS VEGAS	NV	\$ 9,717.00
SHREVEPORT ENDOSCOPY CENTER, A MEDICAL CORPORATION	1V1T13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injactafer- Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia-1	JOHNSON	LAWRENCE	BOSSIER CITY	LA	\$ 2,800.00
SOLLY CHEDID	1V1T14039					\$ 7,080.00
SOUTH BROWARD HOSPITAL DISTRICT	1V1T13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injactafer- Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia-1	LAMET	Mark	HOLLYWOOD	FL	\$ 4,900.00
SOUTH EAST HOSPITAL BASED PHYSICIANS LLC	1V1T13032 Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on Quality of Life and Resource Utilization, of Injactafer- vs. Int	MOSLEY	JAMES	CAPE GIRARDEAU	MO	\$ 45.00
SOUTHWEST UROLOGY, LLC	1V1T14038- A Blinded, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injactafer- Ferric Carboxymaltose- in the Treatment of Iron Deficient patients with Fibromyalgia.	BOOMERSHINE	CHAD	NASHVILLE	TN	\$ 378.00
SRSD INC	1V1T14037	BARI	MOHAMMED	NATIONAL CITY	CA	\$ 34,738.00
ST. JOSEPHS HOSPITAL & MEDICAL CTR	1V1T13032	UCAR	RALUST	GLENDALE	CA	\$ 1,750.00
STANFORD UNIVERSITY	Venue Pediatric Registry	WONG	CYNTHIA	STANFORD	CA	\$ 2,800.00
SYNERGY THERAPY, LLC	1V1T14037- A Double-Blind, Multi-Center, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injactafer- Ferric Carboxymaltose- in the Treatment of Restless Legs Syndrome - RLS-	GUNAWARDANE	RUJWANI	ELLCOTT CITY	MD	\$ 630.00
TAMPA GENERAL HOSPITAL	1V1T14039	JAGLAL	MICHAEL	TAMPA	FL	\$ 16,876.69
TAMPA GENERAL MEDICAL GROUP INC	1V1T14039- A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injactafer- ferric carboxymaltose injection- in Patients with Cancer- and Chemotherapy-related Anemia	JAGLAL	MICHAEL	TAMPA	FL	\$ 80.00
TANNAZ ARMAGHANY	1V1T14039					\$ 7,000.00
TENNESSEE ONCOLOGY PLLC	1V1T13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injactafer- Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia-1	PRUITT	RONALD	NASHVILLE	TN	\$ 1,400.00
TERESA COLEMAN	1V1T14039					\$ 7,160.00
TEXAS UROLOGY GROUP, PA	1V1T13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injactafer- Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia-1	BULLOCK	JEFF	SAN ANTONIO	TX	\$ 2,880.00
THE CENTER FOR GASTROINTESTINAL DISORDERS	1V1T13035	LAMET	Mark	HOLLYWOOD	FL	\$ 61.84
THE JONES CLINIC, PC	1V1T13035	JONES	CLYDE	MEMPHIS	TN	\$ 2,100.00
THE JONES CLINIC, PC	1V1T13035	JONES	CLYDE	MEMPHIS	TN	\$ 2,750.00
THE JONES CLINIC, PC	1V1T14039- A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injactafer- ferric carboxymaltose injection- in Patients with Cancer- and Chemotherapy-related Anemia	JONES	CLYDE	ATLANTA	GA	\$ 21,210.00
THE OREGON CLINIC PC	1V1T13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injactafer- Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia-1	GRUNKMEIER	DAVID	PORTLAND	OR	\$ 378.00
THE POLYCLINIC	1V1T14037	DORESWAMY	MEGHANA	SEATTLE	WA	\$ 33,109.50
THE POLYCLINIC	1V1T14037- A Double-Blind, Multi-Center, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injactafer- Ferric Carboxymaltose- in the Treatment of Restless Legs Syndrome - RLS-	DORESWAMY	MEGHANA	SEATTLE	WA	\$ 7,567.00
THE UNIVERSITY OF TEXAS MEDICAL BR.	1V1T14038	CHEDID	SOLLY	BELTON	TX	\$ 2,000.00
THOMAS ZIMMERMAN	1V1T14037					\$ 9,012.50
THORACIC & VASCULAR ASSOCIATES OF KINSTON PA	1V1T14039- A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injactafer- ferric carboxymaltose injection- in Patients with Cancer- and Chemotherapy-related Anemia	WATSON	PETER	KINSTON	NC	\$ 7,000.00
TIDEWATER GASTROENTEROLOGY, PLLC	1V1T13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injactafer- Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia-1	STOCKWELL	DAVID	VIRGINIA BEACH	VA	\$ 16,500.00
TIDEWATER INTEGRATED MEDICAL SERVICES, PLLC	1V1T13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injactafer- Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia-1	STOCKWELL	DAVID	VIRGINIA BEACH	VA	\$ 5,733.00
TRI-COUNTY HEMATOLOGY AND ONCOLOGY P.A.	1V1T13032 Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on Quality of Life and Resource Utilization, of Injactafer- vs. Int	NAGAJIOTH	NAGAPRASAD	CANTON	OH	\$ 1,800.00
TRI-STATE GASTROENTEROLOGY ASSOCIATES, PSC	1V1T13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injactafer- Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia-1	JONES	MICHAEL	CRESTVIEW HILLS	KY	\$ 420.00
TRI-STATE MOUNTAIN NEUROLOGY ASSOCIATES PC	1V1T14037- A Double-Blind, Multi-Center, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injactafer- Ferric Carboxymaltose- in the Treatment of Restless Legs Syndrome - RLS-	DENGLER	JOHN	JOHNSON CITY	TN	\$ 9,717.00
TX DIGESTIVE DISEASE CONSULTANTS	1V1T13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injactafer- Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia-1	ITTER	TIMOTHY	SOUTHLAKE	TX	\$ 378.00
UNIVERSITY CANCER INSTITUTE LLC	1V1T14039	NIEDERMAN	THOMAS	BOYNTON BEACH	FL	\$ 2,908.00
UNIVERSITY OF KENTUCKY	2NAUC 12001- Xenogenic Collagen Matrix to Increase the Zone of Attached Mucosa Around Implant	AL-SABBAGH	MOHANAD	LEXINGTON	KY	\$ 20,559.75
UNIVERSITY OF NORTH CAROLINA	1V1T13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injactafer- Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia-1	ISAACS	KIM	CHAPEL HILL	NC	\$ 3,001.28
UNIVERSITY OF NORTH CAROLINA HEALTH CARE SYSTEM	1V1T13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injactafer- Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia-1	ISAACS	KIM	CHAPEL HILL	NC	\$ 19,901.32
UNIVERSITY OF SOUTH ALABAMA	1V1T13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injactafer- Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia-1	CASH	BROOKS	MOBILE	AL	\$ 7,300.00
UNIVERSITY OF TX MEDICAL AT GALVESTON	1V1T14039	CHEDID	SOLLY	BELTON	TX	\$ 9,900.00
UNIVERSITY OF MIAMI	1V1T13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injactafer- Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia-1	DESHPANDE	AMAR	MIAMI	FL	\$ 2,800.00

Payee	Study Name	Principal Investigator / Lead Researcher Last Name	Principal Investigator / Lead Researcher First Name	City of PI / Lead Researcher	State of PI / Lead Researcher	Total
WAVERLY HEMATOLOGY ONCOLOGY PA	1VIT14039- A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injectafer- ferric carboxymaltose injection- in Patients with Cancer- and Chemotherapy-related Anemia	GRAHAM	Mark	CARY	NC	\$ 17,830.00
Wellness Oncology and Hematology	1VIT13032 Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on Quality of Life and Resource Utilization, of Injectafer- vs. Int	SHAYE	OMID	WEST HILLS	CA	\$ 378.00
WEST HILLS GASTROENTEROLOGY ASSOCIATES PC	1VIT13035- A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer- Ferric Carboxymaltose- vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron deficient Anemia 4	GRUNKEMEIER	DAVID	PORTLAND	OR	\$ 7,998.00
WESTCHASE CLINICAL ASSOCIATES INC	1VIT14039- A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injectafer- ferric carboxymaltose injection- in Patients with Cancer- and Chemotherapy-related Anemia	ARMAGHANY	TANNAZ	HOUSTON	TX	\$ 567.00
WESTCHASE CLINICAL PLLC	1VIT14039	ARMAGHANY	TANNAZ	HOUSTON	TX	\$ 7,500.00
WILLIAM ONDO	1VIT14037					\$ 11,200.00